About MS Views and News
Within this blog you will find thousands of valuable MS related articles and resources which will enable you to learn and feel empowered with key Multiple Sclerosis information.
From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.
Be empowered with MS news. CLICK HERE -to Subscribe forThe MS BEACON eNewsletter
Plus, learn from the MS Views and News Learning Channel on YouTube: www.youtube.com/msviewsandnews:
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Friday, August 21, 2015
Mobility Aids for Multiple Sclerosis
- The cane should be held on the stronger side of the body while theweight is shifted away from the weaker side.
- A quad cane (or four-legged cane) provides more stability than a standard cane.
HONG KONG — Novartis bolstered its portfolio of multiple sclerosis treatments on Friday by agreeing to buy an experimental drug from GlaxoSmithKline for up to $1 billion, the company said.
Novartis, the Swiss pharmaceutical giant, acquired the rights this year to use the drug, ofatumumab, to treat cancer, and sells it under the name Arzerra. This was part of a broader swap of assets completed in March, in which Novartis took over Glaxo’s cancer drugs and Glaxo took on much of Novartis’s vaccine business.
The deal announced on Friday gives Novartis all remaining rights to ofatumumab, which is being developed to treat relapsing, remitting multiple sclerosis and other autoimmune conditions.
Having the rights under one ownership would avoid the complications that could arise from having two companies selling the same drug for different uses. The deal also bolsters a portfolio of drugs Novartis is developing for multiple sclerosis, centered around its blockbuster pill Gilenya.